Johnson & Johnson Allegedly Pushed Opioids Even After Abuse Became Known; Oklahoma Trial Continues

June 12, 2019 - /PressAdvantage/ - As the Oklahoma trial against Johnson & Johnson for their alleged role in the opioid crisis continues, the state’s star witness told a state judge that the company pressed doctors to prescribe its painkillers even as the potentially fatal addictive threat posed by the drugs became clear more than a decade ago.

The judge, Thad Balkman, is presiding over the non-jury case and will make the final decision in the first trial where a state seeks to hold a drug maker responsible for contributing to the US opioid crisis. Oklahoma is seeking $13 billion in damages from Johnson & Johnson.

Dr. Andrew Kolodny, co-director of opioid policy research at the Heller School for Social Policy and Management at Brandeis University in Waltham, Massachusetts, testified during the third week of the trial. The doctor said that Johnson & Johnson “did everything it possibly could to get doctors to prescribe more and more opioids.”

Oklahoma Attorney General Mike Hunter also claims that Johnson & Johnson’s unit caused a health crisis under the public nuisance theory of law, in an attempt to hold the company accountable for the epidemic. This is traditionally deployed to address real estate disputes over chemical spills, loud noises, etc.

The Oklahoma trial will serve as a preview of how similar claims may play out, as drug makers are facing lawsuits all over the country. Purdue Pharma, the company that created OxyContin is facing thousands of charges across multiple states due to their alleged role in the opioid epidemic. Over 130 Americans are dying from opioid-related overdose every day.

Cities and counties contend that they have spent billions in tax dollars on the societal fall-out from opioid-related overdoses and addictions. This is why they are seeking settlements from large drug manufacturers who allegedly used marketing techniques that downplayed the addictive properties of opioids.

An Oklahoma bench trial that started May 28 could take 2-3 months. A deal may be unlikely during trial unless the state makes concessions, given it would show weakness on the part of Johnson & Johnson.

Kolodny told Balkman that Johnson & Johnson profited even more from the crisis through its ownership of Australian poppy cultivator Tasmanian Alkaloids, which sold its active ingredient to other opioid makers including the company’s former co-defendants in the Oklahoma case, Purdue Pharma and Teva Pharmaceutical.

Johnson & Johnson has since sold the business. In March, Purdue reached a settlement for $270 million. Teva agreed to pay $85 million days before the trial started on May 28.

Johnson & Johnson maintain they legally promoted and sold their Fentanyl-based Duragesic pain patch. They said that the company should not be held responsible for the misdeeds of other companies. Click the link to see Daytona's top rehab placement programs.

Johnson & Johnson’s defense attorney Larry Ottaway noted that other companies had settled when his client had not, saying at the trial’s outset: “when you are right, you fight.”

Another lawyer for Johnson & Johnson said: “the testimony of Dr. Kolodny was filled with rampant speculation and conclusions not derived from facts.”

Kolodny has been active in the study and treatment of opioid addiction for more than a decade. He also worked with the New York City Health Department during the mayoral administration of Michael Bloomberg, founder and majority owner of Bloomberg News parent Bloomberg LP.

Kolodny told Balkman that Johnson & Johson, along with other opioid makers, should not market their products as hard to abuse since all have addictive qualities. They also allegedly used what the US Food and Drug Administration concluded were unreliable studies to tout Duragesic’s benefits as a pain reliever. The company may have also violated federal law by doing head-to-head comparisons of the pain patch’s advantages over Purdue’s OxyContin.

If someone in the family is struggling with opioid or alcohol addiction, it is important to seek help. A combination of medical detox and behavioral therapy can go a long way in the fight against drug abuse. But because every individual is affected by addiction differently, a comprehensive program tailored to their specific needs is necessary. Look for a nearby addiction treatment facility today and find out how drug treatment programs work.

###

For more information about Rehab Near Me: Daytona Beach, contact the company here:

Rehab Near Me: Daytona Beach
+1 863-862-5822

ReleaseID: 60028809

Latest News

Global shares mostly rise after Wall Street rally on Huawei

Aug 21, 2019

TOKYO — Global shares were mostly higher Tuesday after Wall Street rallied on the U.S. decision to give Chinese telecom giant Huawei another 90 days to buy equipment from American suppliers. That decision appeared to inspire a buying mood among investors eager for any signs of progress in the trade war between the U.S. and China. France's CAC 40 added nearly 0.2% in early trading to 5,380.18, while Germany's DAX inched up nearly 0.1% to 11,723.98. Britain's FTSE 100 rose 0.2% to 7,205.60. U.S. shares were set to drift higher with Dow futures edging up 0.1% to 26,143. S&P 500...

Die-hard Hong Kong protesters defend tactics as unity cracks

Aug 21, 2019

HONG KONG — On a recent sweltering Saturday, a day now reserved for protest in Hong Kong, a demonstrator named Wayne stepped past a row of plastic barricades, lifted a pair of binoculars and squinted. Four hundred meters away, a line of riot police stood with full-length shields, batons and tear-gas launchers. It was a familiar sight for Wayne after more than two months on the front lines of Hong Kong's pro-democracy demonstrations. Face-offs with police have become part of the 33-year-old philosophy professor's new normal. The stories of Wayne and three other self-described "front line" protesters interviewed by The...

Asian shares rise as investors watch trade war, economies

Aug 21, 2019

TOKYO — Asian shares were higher Monday, as investors continue to rejigger their read on President Donald Trump's trade war and growing worries about slowing economies around the world. Japan's benchmark Nikkei 225 rose 0.6% in early trading to 20,532.95. Australia's S&P/ASX 200 gained 0.8% to 6,454.40, while South Korea's Kospi was 0.4% higher at 1,934.78. Hong Kong's Hang Seng rose 0.9% to 25,734.22. The Shanghai Composite added 0.3% to 2,823.82. On Friday, the S&P 500 rose 41.08 points, or 1.4%, to 2,888.68. The Dow, which had an 800-point drop earlier in the week, added 306.62 points, or 1.2%, to...

Japan's exports fell in July for 8th straight month

Aug 21, 2019

TOKYO — Japan's exports fell for the eighth straight month in July as worries continued about President Donald Trump's trade policies denting Asian economic growth. Ministry of Finance data released Monday showed exports and imports fell in July, compared to the same month a year ago. Exports fell 1.6%, while imports slid 1.2%, resulting in a trade deficit of 249.6 billion yen ($2.35 billion). Global markets have been in turmoil because of Trump's trade war with China. A slowdown in China is certain to hurt other regional economies, including Japan's. Japan's exports to China in July fell 9.3% while its...

Cathay Pacific CEO resigns after Beijing pressure

Aug 21, 2019

HONG KONG — The CEO of Cathay Pacific Airways, one of Hong Kong's most prominent companies, resigned Friday following pressure by Beijing on the carrier over participation by some of its employees in anti-government protests. Rupert Hogg became the highest-profile corporate casualty of official Chinese pressure on foreign and Hong Kong companies to support the ruling Communist Party's position against the protesters. Beijing jolted companies last week when it warned Cathay Pacific employees who "support or take part in illegal protests" would be barred from flying to or over the mainland. Cathay Pacific said a pilot who was charged with...

Subscribe To Our Newsletter